Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04161391 · ClinicalTrials.gov registry record · Phase 1
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
A Phase 1 study, sponsored by Turning Point Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT04161391 is a Phase 1 study that was terminated before completion, run by Turning Point Therapeutics. The registered enrollment target is 41 participants.
The verdict
NCT04161391, a Phase 1 study, was terminated before completion, sponsored by Turning Point Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced or metastatic solid tumors harboring RET mutations or alterations. The study consists of three portions: 1) Phase 1 Dose Escalation and Food Effect Sub-study, and 2) Phase 1 dose expansion and 3) Phase 2 efficacy evaluation.
Interventions
- DRUG TPX-0046
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2019-12-06 |
| Est. Completion | 2023-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04161391
The ClinicalTrials.gov registry entry for NCT04161391 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Turning Point Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TPX-0046 is the first listed.
NCT04161391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04161391 about?
NCT04161391 is a clinical study titled "Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations". A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced or metastatic solid tumors harboring RET mutations or alterations. The study consists of three portions: 1) Phase ...
What is the current status of trial NCT04161391?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2019-12-06. Estimated completion is 2023-05-22.
What interventions are being tested in trial NCT04161391?
The interventions under investigation include: TPX-0046 (DRUG).
Who is sponsoring clinical trial NCT04161391?
This trial is sponsored by Turning Point Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.